Finally, these findings have therapeutic implications for the management of both FL and DLBCL patients, as they provide additional rationale for the combinatorial targeting of CREBBP (e.g., by using HDAC3 small-molecule inhibitors) (42, 51) and KMT2D defects (e.g., by using KDM5 demethylase inhibitors) (52) in cases where both genes are mutated. Here, CREBBP is linked to diffuse large B-cell lymphoma.